BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schaffer PC, Kulkarni PM, Janero DR, Thakur GA. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Bioorg Med Chem 2020;28:115727. [PMID: 33065437 DOI: 10.1016/j.bmc.2020.115727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem 2021;50:116421. [PMID: 34634617 DOI: 10.1016/j.bmc.2021.116421] [Reference Citation Analysis]
2 Manning JJ, Green HM, Glass M, Finlay DB. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias. Neuropharmacology 2021;193:108611. [PMID: 34000272 DOI: 10.1016/j.neuropharm.2021.108611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, Thakur GA. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem 2021;64:8104-26. [PMID: 33826336 DOI: 10.1021/acs.jmedchem.1c00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]